Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Chronic treatment of db/db mice with Roflumilast N-oxide at 3 mg/kg shows prevention of disease progression
Neuropsychopharmacology 33 2362
InChi: InChI=1S/C15H19N7O3S/c1-26(23
Chemical Name: 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-[(3R)-piperidin-3-yl]-1H
Canagliflozin - CAS# 842133-18-0 Catalog No.:M10730-10 Chronic treatment of db/db miceCanagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the
US$ 11.00
US$ 124.95
US$ 79.00
US$ 24.99